[go: up one dir, main page]

AR035352A1 - Anticuerpos anti-lt-beta-r humanizados - Google Patents

Anticuerpos anti-lt-beta-r humanizados

Info

Publication number
AR035352A1
AR035352A1 ARP010104807A ARP010104807A AR035352A1 AR 035352 A1 AR035352 A1 AR 035352A1 AR P010104807 A ARP010104807 A AR P010104807A AR P010104807 A ARP010104807 A AR P010104807A AR 035352 A1 AR035352 A1 AR 035352A1
Authority
AR
Argentina
Prior art keywords
beta
humanized antibodies
methods
humanized
antibodies
Prior art date
Application number
ARP010104807A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AR035352A1 publication Critical patent/AR035352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos humanizados para LT-beta-R y métodos de uso de los mismos.
ARP010104807A 2000-10-13 2001-10-12 Anticuerpos anti-lt-beta-r humanizados AR035352A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
AR035352A1 true AR035352A1 (es) 2004-05-12

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104807A AR035352A1 (es) 2000-10-13 2001-10-12 Anticuerpos anti-lt-beta-r humanizados

Country Status (25)

Country Link
US (2) US7429644B2 (es)
EP (1) EP1326897A2 (es)
JP (1) JP2004532608A (es)
KR (1) KR20030041164A (es)
CN (1) CN1547590A (es)
AR (1) AR035352A1 (es)
AU (2) AU1174702A (es)
BG (1) BG107802A (es)
BR (1) BR0114646A (es)
CA (1) CA2425809A1 (es)
CZ (1) CZ20031307A3 (es)
EA (1) EA006945B1 (es)
EE (1) EE200300179A (es)
GE (1) GEP20063752B (es)
HU (1) HUP0302573A2 (es)
IL (1) IL155340A0 (es)
IS (1) IS6779A (es)
MX (1) MXPA03003144A (es)
NO (1) NO20031642L (es)
NZ (1) NZ525793A (es)
PL (1) PL366307A1 (es)
SK (1) SK5672003A3 (es)
TR (2) TR200300478T2 (es)
WO (1) WO2002030986A2 (es)
YU (1) YU28503A (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
TWI422387B (zh) * 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
JP5298021B2 (ja) 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
WO2008049053A2 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN106084054A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
TN2018000021A1 (en) 2015-07-14 2019-07-08 Immunext Inc ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US20210188990A1 (en) 2019-12-11 2021-06-24 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
AU2024253044A1 (en) 2023-04-07 2025-10-02 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU692146B2 (en) 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
EP0536299B1 (en) 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
EA003862B1 (ru) 1998-01-30 2003-10-30 Байоджен, Инк. Способ прекращения или замедления развития фолликулярной лимфомы и композиции для его осуществления
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CN1678625A (zh) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
RS20050481A (sr) 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
AU2003299984A1 (en) 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2002211747B2 (en) 2007-11-29
CA2425809A1 (en) 2002-04-18
EA200300464A1 (ru) 2003-10-30
BG107802A (bg) 2004-01-30
KR20030041164A (ko) 2003-05-23
EP1326897A2 (en) 2003-07-16
US20040058394A1 (en) 2004-03-25
TR200300478T2 (tr) 2004-10-21
HUP0302573A2 (hu) 2003-10-28
YU28503A (sh) 2006-05-25
GEP20063752B (en) 2006-02-27
IS6779A (is) 2003-04-11
JP2004532608A (ja) 2004-10-28
CN1547590A (zh) 2004-11-17
EA006945B1 (ru) 2006-06-30
IL155340A0 (en) 2003-11-23
NZ525793A (en) 2008-04-30
EE200300179A (et) 2003-08-15
WO2002030986A3 (en) 2003-03-13
SK5672003A3 (en) 2003-10-07
NO20031642D0 (no) 2003-04-10
AU1174702A (en) 2002-04-22
TR200602095T2 (tr) 2007-02-21
US7429644B2 (en) 2008-09-30
CZ20031307A3 (cs) 2003-10-15
PL366307A1 (en) 2005-01-24
WO2002030986A2 (en) 2002-04-18
MXPA03003144A (es) 2004-12-06
BR0114646A (pt) 2006-02-21
NO20031642L (no) 2003-06-13
US20090092601A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
AR035352A1 (es) Anticuerpos anti-lt-beta-r humanizados
DE60010098D1 (de) 28-epirapaloge
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
ECSP088831A (es) Anticuerpos anti-tat226 e inmunoconjugados
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
AR027938A1 (es) Compuestos uracilo y utilizacion de los mismos
CR10734A (es) Anticuerpos e inmunoconjugados y sus usos
DE60106954D1 (de) Resorcin-derivate
CR8231A (es) Anticuerpos rg1 y uso de los mismos
ES2187200T3 (es) Proteina hibrida para inhibir la desgranulacion de mastocitos y su uso.
UY27192A1 (es) Inhibidores de peptido-deformilasa
NO20031860D0 (no) Kahalaolid F
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
BR0015872A (pt) Agentes antitrombóticos
UY26556A1 (es) Compuestos calcilíticos
BR0110902A (pt) Inibidores de mmp-9/mmp-2
BR0112600A (pt) Compostos calcilìticos
DK1311267T3 (da) Retroviral immunoterapi
BR0316544A (pt) Compostos calcilìticos
ATE256754T1 (de) Gerbstoff-/nachgerbstoffpräparationen
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
UA3864S (uk) Комплект туристських меблів
FR2811851B3 (fr) Perfectionnements concernant les telephones portables
AR027950A1 (es) Novedoso uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal